| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/03/2011 | CN102140441A Bird flu vaccine by using attenuated vaccinia Tian Tan as vector |
| 08/03/2011 | CN102140430A Mouse-typhus salmonella gene-deletion mutant strain without containing resistance marks, vaccine and application thereof |
| 08/03/2011 | CN102140139A Antitumor human single-chain antibody |
| 08/03/2011 | CN102139116A Preparation method of envelope protein A gene vaccine for fowl cholera |
| 08/03/2011 | CN102139106A Binding molecules capable of neutralizing rabies virus and uses thereof |
| 08/03/2011 | CN102139105A Immunotherapy method |
| 08/03/2011 | CN102139104A Production method for triple inactivated vaccine for newcastle disease, avian influenza (H9 subtype) and infectious bursal disease |
| 08/03/2011 | CN102139103A Preparation and application methods of photobacterium damsela vaccines of cynoglossus semilaevis |
| 08/03/2011 | CN102139102A Preparation method of microcapsule vaccines capable of resisting infection of aeromonas hydrophila |
| 08/03/2011 | CN102139101A Application of protein Com1 in immunoprotection of coxiella burnetii |
| 08/03/2011 | CN102139100A Application of protein Mip in immune protection of coxiella burnetii |
| 08/03/2011 | CN101629151B Brucella abortus immune marking recombinant strain and application thereof in preparation of vaccine |
| 08/03/2011 | CN101629149B Marker-free gene-deletion attenuated mutant strain derived from Edwardsiella tarda wild strain, related preparation and application thereof |
| 08/03/2011 | CN101525378B Listonella anguillarum subunit vaccine antigenic protein and application thereof |
| 08/03/2011 | CN101495632B Humanized anti-human osteopontin antibody |
| 08/03/2011 | CN101316590B Use of combination of anti-angiogenic substance and c-kit kinase inhibitor |
| 08/03/2011 | CN101311190B Antigen epitope for exciting protective immunity against tubercle bacillus of human body and uses thereof |
| 08/02/2011 | US7989605 Compounds and methods for immunotherapy and diagnosis of tuberculosis |
| 08/02/2011 | US7989597 Immunogenic memapsin 2 β-secretase peptides and methods of use |
| 08/02/2011 | US7989596 Method of altering the binding specificity of monoclonal antibodies by oxidation-reduction reactions |
| 08/02/2011 | US7989595 Compositions and methods for the diagnosis and treatment of tumor |
| 08/02/2011 | US7989594 Modified antibody fab fragments |
| 08/02/2011 | US7989425 Vaccine enhancing the protective immunity to hepatitis c virus using plasmid DNA and recombinant adenovirus |
| 08/02/2011 | US7989203 Methods for use of apoptotic cells to deliver antigen to dendritic cells for induction or tolerization of T cells |
| 08/02/2011 | US7989182 Nucleic acid encoding SCN1A variant |
| 08/02/2011 | US7989162 Viral variants with altered susceptibility to nucleoside analogs and uses thereof |
| 08/02/2011 | US7989161 Methods for determining human immunodeficiency virus type 2 (HIV-2) protease sensitivity or resistance to antivirals utilizing an inducible yeast expression system |
| 08/02/2011 | US7988980 Tuberculosis vaccine with improved efficacy |
| 08/02/2011 | US7988979 Neisseria meningitidis antigens and compositions |
| 08/02/2011 | US7988978 Composition and method for controlling intestinal pathogenic organisms |
| 08/02/2011 | US7988977 Modified live Aeromonas hydrophila vaccine for aquatic animals |
| 08/02/2011 | US7988975 Modified HIV-1 group M cyclic gp41 peptides and their use in the detection of anti-HIV-1 antibodies |
| 08/02/2011 | US7988974 comprise a macromolecular carrier group fused to a gp41-derived DP178 peptide corresponding to amino acids 638 to 673 of the HIV-1LA1 gp41 protein; inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells |
| 08/02/2011 | US7988973 Activin-ActRII antagonists and uses for increasing red blood cell levels |
| 08/02/2011 | US7988972 Immunoreactive peptides from Epstein-Barr virus |
| 08/02/2011 | US7988971 Human monoclonal antibodies against Hendra and Nipah viruses |
| 08/02/2011 | US7988970 Methods of treatment comprising administering an anti-sclerostin antibody |
| 08/02/2011 | US7988969 Treatment for central nervous system disorders |
| 08/02/2011 | US7988968 Method of treating an IL-1 related coronary condition |
| 08/02/2011 | US7988967 High affinity human antibodies to human nerve growth factor |
| 08/02/2011 | US7988966 Method for the potentiation of opioid analgesics effects on pain |
| 08/02/2011 | US7988965 Methods of treating systemic lupus erythematosus with an antibody against costimulatory signal transduction molecule ailim |
| 08/02/2011 | US7988964 NOGO-a neutralising immunoglobulin for treatment of neurological diseases |
| 08/02/2011 | US7988963 Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses |
| 08/02/2011 | US7988958 Enterococcus and Streptococcus strains and bacteriocins |
| 08/02/2011 | US7988951 Method for inducing selectively suppressed immune response to transplanted tissue or cells |
| 08/02/2011 | CA2486678C Non-viral gene delivery system |
| 08/02/2011 | CA2475395C Anti-human tenascin monoclonal antibody |
| 08/02/2011 | CA2442682C Monocyte-specific particulate delivery vehicle |
| 08/02/2011 | CA2441690C Method for the identification of antigenic peptides |
| 08/02/2011 | CA2436623C Branched polyalkylene glycols |
| 08/02/2011 | CA2417984C Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30l |
| 08/02/2011 | CA2417255C Medicament comprising amrubicin and an anti-her2 antibody for treating breast cancer |
| 08/02/2011 | CA2412650C Pleiotrophin growth factor receptor for the treatment of proliferative, vascular and neurological disorders |
| 08/02/2011 | CA2370187C Treatment of neoplasms with viruses |
| 08/02/2011 | CA2323757C Antibody variants and fragments thereof |
| 08/02/2011 | CA2282300C Recombinant pox virus for immunization against muc1 tumor-associated antigen |
| 08/02/2011 | CA2265498C Staphylococcus aureus antigen |
| 08/02/2011 | CA2107569C Parathyroid hormone receptor and dna encoding same |
| 08/02/2011 | CA1341619C Recombinant inhibin |
| 07/28/2011 | WO2011091435A2 Methods of treating liver disease |
| 07/28/2011 | WO2011091401A2 Treatment of immune disorders using kainate receptor antagonists |
| 07/28/2011 | WO2011091376A2 Immunogenic influenza composition |
| 07/28/2011 | WO2011091366A2 Methods of treating or preventing periodontitis and diseases associated with periodontitis |
| 07/28/2011 | WO2011091319A2 Dendritic cell vaccines |
| 07/28/2011 | WO2011091305A2 Inhibition of axl signaling in anti-metastatic therapy |
| 07/28/2011 | WO2011091304A1 Delivery system for diagnostic and therapeutic agents |
| 07/28/2011 | WO2011091279A2 Targeted heterologous antigen presentation on calicivirus virus-like particles |
| 07/28/2011 | WO2011091255A1 Vaccine vectors and methods of enhancing immune responses |
| 07/28/2011 | WO2011091181A1 Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments |
| 07/28/2011 | WO2011091177A1 Anti-ilt5 antibodies and ilt5-binding antibody fragments |
| 07/28/2011 | WO2011091167A2 Lysophosphatidic acid receptor targeting for scleroderma and other fibrotic diseases |
| 07/28/2011 | WO2011091154A2 Use of human erythrocytes for prevention and treatment of cancer dissemination and growth |
| 07/28/2011 | WO2011091027A2 Recombinant live attenuated foot-and-mouth disease (fmd) vaccine containing mutations in the l protein coding region |
| 07/28/2011 | WO2011090973A2 Immunotherapy compositions and methods of treatment |
| 07/28/2011 | WO2011090926A1 Nutritional formulas containing synbiotics |
| 07/28/2011 | WO2011090762A1 Heterodimer binding proteins and uses thereof |
| 07/28/2011 | WO2011090761A1 Ron binding constructs and methods of use thereof |
| 07/28/2011 | WO2011090754A1 Polypeptide heterodimers and uses thereof |
| 07/28/2011 | WO2011090712A2 Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions |
| 07/28/2011 | WO2011090648A2 Inhibitors of vascular endothelial growth factor (vegf) receptors and methods of use thereof |
| 07/28/2011 | WO2011090492A1 Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r) |
| 07/28/2011 | WO2011090283A2 Composition containing inhibitors of the expression or activity of sh3rf2 for preventing or treating cancer |
| 07/28/2011 | WO2011090266A2 Novel tumor antigen protein agr2 and tumor antigenic peptide thereof |
| 07/28/2011 | WO2011090088A1 Solution preparation containing stabilized antibody |
| 07/28/2011 | WO2011090065A1 Peptide vaccine |
| 07/28/2011 | WO2011090005A1 Pharmaceutical preparation for colon cancer, and treatment method |
| 07/28/2011 | WO2011089183A2 Anticoagulant antidotes |
| 07/28/2011 | WO2011089101A1 Tumor tissue based biomarkers for bevacizumab combination therapies |
| 07/28/2011 | WO2011089004A1 Cancer stem cell markers and uses thereof |
| 07/28/2011 | WO2011088843A1 Enterococcal cell wall components and antibacterial use thereof |
| 07/28/2011 | WO2011068801A3 Methods for identifying compounds that modulate ion channel activity of a kir channel |
| 07/28/2011 | WO2011059755A3 Dual variable domain immunoglobulins and uses thereof |
| 07/28/2011 | WO2011053783A3 Ax213 and ax132 pcsk9 antagonists and variants |
| 07/28/2011 | WO2008137733A3 Micellar structures, methods of making micellar structures, methods of imaging, and methods of delivering agents |
| 07/28/2011 | US20110184330 Inactivation of smooth muscle tissue |
| 07/28/2011 | US20110184145 Method of administering therapeutic polypeptides, and polypeptides therefor |
| 07/28/2011 | US20110183923 Peptide antagonists of zonulin and methods for use of the same |
| 07/28/2011 | US20110183412 Alteration of fc-fusion protein serum half-lives by mutagenesis |
| 07/28/2011 | US20110183375 Metal binding compounds and their use in cell culture medium compositions |